We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Lupus Anticoagulant Prolongs Activated Partial-Thromboplastin Time in COVID-19

By LabMedica International staff writers
Posted on 20 May 2020
Patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state, and complicating venous thrombotic events are common. More...
Abnormalities in coagulation screening measures, including a prolonged activated partial-thromboplastin time (aPTT), have been reported in patients with COVID-19.

A prolonged aPTT may indicate a clotting-factor deficiency or the presence of an inhibitor of coagulation that is either specific such as antibody to factor VIII or nonspecific such as lupus anticoagulant. Lupus anticoagulant can affect in vitro tests of blood coagulation, but typically is not associated with bleeding. As part of the antiphospholipid syndrome, lupus anticoagulant is associated with a thrombotic risk.

A team of Medical Scientists at the Royal London Hospital (London UK) and their associates investigated the cause of prolonged aPTT in 35 patients (median age, 57 years; 24 were male) with COVID-19 who were treated at the hospital. At the time of sampling, 21 patients were tested while in critical care, 10 were from in-patients or Emergency Department (ED) patients were admitted for >24 hours, and four were from ED patients who were discharged within 24 hours. Pulmonary embolism was confirmed in one patient, and clinically suspected thrombosis was present in one patient.

None of the patients had deficiencies in factor VIII or factor IX. In five patients, marginal reductions in factor XI were found that were unlikely to be of clinical significance. The factor XII level was ≤50 IU/dL in 16 patients. Coagulation assays were performed on Sysmex CS-series analyzers (Sysmex Corporation, Kobe, Japan). Lupus anticoagulant (LA) screening assays were performed using Siemens LA1 reagent for dilute Russell’s Viper Venom Time (DRVVT, Siemens Healthineers, Erlangen, Germany), and Diagnostica Stago PTT-LA reagent (Diagnostica Stago, Reading, UK) for APTT.

Lupus anticoagulant assays were performed in 34 patients, and 31 (91%) were positive. The presence of lupus anticoagulant was indicated by two assays in 18 of the 34 (53%) patients, by DRVVT alone in seven (21%), and by lupus anticoagulant-sensitive aPTT alone in six (18%). All samples that were positive for lupus anticoagulant had a prolonged aPTT with a 50:50 mix (sample made up of 50% patient plasma and 50% normal plasma).

In a historical control cohort of 540 specimens received for lupus anticoagulant testing, 43 (8%) had an aPTT of ≥30 seconds, and 11 of the 43 (26%) were positive for lupus anticoagulant. The percentage of specimens that were positive for lupus anticoagulant was significantly higher among the patients with COVID-19 than in the control cohort.

The authors suggested that a prolonged aPTT should not be a barrier to the use of anticoagulation therapies in the prevention and treatment of venous thrombosis in patients with COVID-19. In their opinion, clinicians should not withhold use of anticoagulants for thrombosis while awaiting further investigation of a prolonged aPTT, nor should they withhold thrombolytic therapy in the face of a high-risk pulmonary embolism on the basis of a prolonged aPTT alone. The study was published on May 5, 2020 in The New England Journal of Medicine.



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.